EUVIMEDEUVIMED entdecken
Leitlinie

NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024

John A Thompson, Bryan J Schneider, Julie Brahmer, Mohammad Abu Zaid, Amaka Achufusi, Philippe Armand, Meghan K Berkenstock, Bonnie Bermas, Tawnie Braaten, Lihua E Budde, Saurin Chokshi, Zachary D Crees und 33 weitere

Journal of the National Comprehensive Cancer Network · 2024-11 · 22 (9) · 582-592

DOI: 10.6004/jnccn.2024.0057 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2024-11. Verfasst von John A Thompson und 44 weiteren Autor:innen. Beteiligte Einrichtung: 1Fred Hutchinson Cancer Center. Hauptthemen laut MEDLINE: Immunotherapy, Neoplasms. Die Arbeit wurde bisher 175-mal zitiert (Crossref) und nennt 55 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The NCCN Guidelines for the Management of Immunotherapy-Related Toxicities are intended to provide oncology practitioners with guidance on how to manage the wide-ranging and potentially fatal toxicities that may occur with cancer immunotherapy. The guidelines address immune-related adverse events related to immune checkpoint inhibitors, CAR T-cell therapies, and lymphocyte engagers (which include T-cell–engaging bispecific antibodies). These NCCN Guidelines Insights highlight recent guideline updates pertaining to the management of emerging toxicities related to cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyNeoplasmsHumansImmune Checkpoint InhibitorsDrug-Related Side Effects and Adverse ReactionsDisease ManagementMedical Oncology

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • 1Fred Hutchinson Cancer Center.
  • 2University of Michigan Rogel Cancer Center.
  • 3Johns Hopkins Kimmel Cancer Center.
  • 4Indiana University Melvin and Bren Simon Comprehensive Cancer Center.
  • 5University of Wisconsin Carbone Cancer Center.
  • 6Dana-Farber Cancer Institute.

Zitieren

APA

Thompson, J. A., Schneider, B. J., Brahmer, J., Zaid, M. A., Achufusi, A., Armand, P., Berkenstock, M. K., Bermas, B., Braaten, T., Budde, L. E., Chokshi, S., Crees, Z. D., Davies, M., Deng, C., Gesthalter, Y., Jain, M., Jain, P., Jallouk, A., Kaffenberger, B. H., …, & Hang, L. (2024). NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024. Journal of the National Comprehensive Cancer Network, 22(9), 582-592. https://doi.org/10.6004/jnccn.2024.0057

Vancouver

Thompson JA, Schneider BJ, Brahmer J, Zaid MA, Achufusi A, Armand P, et al. NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024. Journal of the National Comprehensive Cancer Network. 2024;22(9):582-592. doi:10.6004/jnccn.2024.0057

BibTeX
@article{Thompson2024,
  author = {Thompson, John A and Schneider, Bryan J and Brahmer, Julie and Zaid, Mohammad Abu and Achufusi, Amaka and Armand, Philippe and Berkenstock, Meghan K and Bermas, Bonnie and Braaten, Tawnie and Budde, Lihua E and Chokshi, Saurin and Crees, Zachary D and Davies, Marianne and Deng, Changchun and Gesthalter, Yaron and Jain, Michael and Jain, Prantesh and Jallouk, Andrew and Kaffenberger, Benjamin H and Khalil, Maya and Lechner, Melissa G and Li, Tianhong and Marr, Alissa and McGettigan, Suzanne and McPherson, Jordan and Medina, Theresa and Mohindra, Nisha A and Olszanski, Anthony J and Oluwole, Olalekan and Patel, Sandip P and Prosek, Jason and Reddy, Sunil and Reid, Pankti and Ryan, John and Ryder, Mabel and Salman, Huda and Santomasso, Bianca and Shofer, Scott and Sosman, Jeffrey A and Wang, Yinghong and Zaha, Vlad G and Zucker, Stephen and Lyons, Megan and Awotiwon, Ajibola and Hang, Lisa},
  title = {NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024},
  journal = {Journal of the National Comprehensive Cancer Network},
  year = {2024},
  volume = {22},
  number = {9},
  pages = {582--592},
  doi = {10.6004/jnccn.2024.0057}
}
Kostenlos starten →